CN103374540B - Corynebacterium glutamicum and application thereof - Google Patents
Corynebacterium glutamicum and application thereof Download PDFInfo
- Publication number
- CN103374540B CN103374540B CN201310351990.9A CN201310351990A CN103374540B CN 103374540 B CN103374540 B CN 103374540B CN 201310351990 A CN201310351990 A CN 201310351990A CN 103374540 B CN103374540 B CN 103374540B
- Authority
- CN
- China
- Prior art keywords
- corynebacterium glutamicum
- glutaminate
- cgmcc
- deposit number
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186226 Corynebacterium glutamicum Species 0.000 title claims abstract description 51
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 68
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 238000000855 fermentation Methods 0.000 claims abstract description 18
- 230000004151 fermentation Effects 0.000 claims abstract description 18
- 239000002609 medium Substances 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 9
- 238000011218 seed culture Methods 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 240000008042 Zea mays Species 0.000 claims description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 8
- 235000005822 corn Nutrition 0.000 claims description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000011790 ferrous sulphate Substances 0.000 claims description 4
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 15
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 8
- 229960005322 streptomycin Drugs 0.000 abstract description 6
- 229930193140 Neomycin Natural products 0.000 abstract description 5
- 229960004927 neomycin Drugs 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 229930182816 L-glutamine Natural products 0.000 abstract 5
- 238000004321 preservation Methods 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 description 26
- 230000001580 bacterial effect Effects 0.000 description 25
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 21
- 229960002989 glutamic acid Drugs 0.000 description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 16
- 235000013922 glutamic acid Nutrition 0.000 description 16
- 239000004220 glutamic acid Substances 0.000 description 16
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 12
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 229940126575 aminoglycoside Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920001807 Urea-formaldehyde Polymers 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- -1 amino glucosides Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- 241000186312 Brevibacterium sp. Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000191936 Micrococcus sp. Species 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229950001902 dimevamide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to the microbial field, and discloses corynebacterium glutamicum strains and application thereof. A corynebacterium glutamicum MHZ-0510 strain has a preservation number CGMCC No.7939; a corynebacterium glutamicum MHZ-0511 strain has a preservation number CGMCC No.7940; the two strains have significantly improved ability of fermentation for generating L-glutamine, compared with that of the original strain of wild type of corynebacterium glutamicum B498, and can be widely applied to fermentation production of L-glutamine. The corynebacterium glutamicum strains involved in the invention are obtained by screening aminoglycoside antibiotics, such as streptomycin and neomycin, have resistance to the aminoglycoside antibiotics including streptomycin and neomycin, and have improved ability to synthesis of L-glutamine, thus increasing the yield of L-glutamine. Therefore, aminoglycoside antibiotics can be widely applied to screen of L-glutamine.
Description
Technical field
The present invention relates to microorganism field, relate to Corynebacterium glutamicum and application thereof specifically.
Background technology
L-glutaminate, formal name used at school is 2-amino-5-carboxyl valeramide, is the acid amides of L-glutamic acid.L-glutaminate molecular formula is C
10h
20n
4o
6, molecular weight is 292.289, and structural formula is
L-glutaminate is one of amino acid the abundantest in body fluid, and accounting for 61% of human body total free aminoacids, is the conditionally essential amino acid that human body is the most general, can not lack.L-glutaminate major storage in human body is in skeletal muscle, and its concentration is higher than 30 times of internal milieu, just discharges when needing.L-glutaminate has multiple effect, as immunologic function can be strengthened, safeguard acid base equilibrium, increase cell volume, the synthesis of strengthen muscle cell protein, participate in the biosynthesizing of the mucoprotein constituent glucosamine of alimentary canal mucous membrane, thus promote the reparation of mucosal epithelium, contribute to the elimination of ulcer focus.Meanwhile, L-glutaminate promotes brain metabolism by hemato encephalic barrier, improves brain function, and the same with L-glutamic acid is the important nutrition agent of brain metabolism.In addition, L-glutaminate also can be used for treating the fatigue recovery after athletic movement syndrome and highly intensive labour or work, rebuilds immunity system, is conducive to treatment and supports liver function, reducing the side effect of radiation and chemotherapy in cancer therapy.So a kind of important biochemical reagents are not only by glutamine, be also a kind of extremely rising new drug simultaneously.
L-glutaminate is widely used abroad as medicinal amino acid, and Germany is loaded into pharmacopeia because it has good curative effect in the diseases such as stomach ulcer, gastritis, duodenal ulcer as medicine; In Japan, L-glutaminate has obtained general use as stomach and intestine class medicine and strong sirloin product; The health care medicine that the U.S. is used for the treatment of the diseases such as stomach ulcer is also quite extensive to the use of L-glutaminate; China also due to the excellent characteristics in the recovery of its patient after surgery, and is widely used in medical industry.
The production method of L-glutaminate mainly contains chemical synthesis, enzymic synthesis and fermentation method.Wherein chemical synthesis reactions steps is various.Although and enzymic synthesis reactions steps relatively simply but wherein required reactant Triphosaden (ATP) is expensive, the substrate of enzymatic reaction simultaneously NH
4+, byproduct adenosine diphosphate (ADP) (ADP) all obviously suppresses the generation of L-glutaminate, therefore can not meet the needs of large-scale industrial production.And fermentation method has the advantages such as raw material sources are extensive, production cost is low, quality product is controlled, product is single, it is therefore L-Gln production method the most frequently used at present.
L-glutaminate output height is inseparable with adopted microbial strains, L-glutaminate produces bacterial classification mainly from glutamate producing bacterium, as bar bacterium (Corynebacterium sp.), tyrothricin (Brevibacterium sp.), micrococci (Micrococcus sp.).In addition, non-glutamic acid is also had to produce bacterium, as some variation bacterial classifications of flavobacterium (Flavobacterium rigense).Wherein Corynebacterium glutamicum is one of bacterial classification conventional in L-glutaminate fermentation, but its L-glutaminate output is not high, far can not meet the large-scale industrial production of L-glutaminate.
Summary of the invention
In view of this, the object of the present invention is to provide Corynebacterium glutamicum and application thereof, to improve the output of L-glutaminate, meet the large-scale industrial production of L-glutaminate.
For achieving the above object, the present invention adopts following technical scheme:
The invention provides a kind of Corynebacterium glutamicum, be deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, deposit number is CGMCC No.7939.
Invention also provides the application of Corynebacterium glutamicum in production L-glutaminate that deposit number is CGMCC No.7939.
Present invention also offers a kind of Corynebacterium glutamicum, be deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, deposit number is CGMCC No.7940.
Invention also provides the application of Corynebacterium glutamicum in production L-glutaminate that deposit number is CGMCC No.7940.
Present invention also offers a kind of production method of L-glutaminate, the Corynebacterium glutamicum of to be CGMCC No.7939 or deposit number by deposit number be CGMCC No.7940 is inoculated in seed culture medium, and to carry out expansion numerous, then by expand numerous after culture proceed to fermention medium fermentation, maintaining pH value between yeast phase is 4-8.
As preferably, the pH value between described yeast phase is 4.9-7.4.
As preferably, described seed culture medium is made up of 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L magnesium sulfate, 5.5g/L urea, and pH value is 7.0-7.2.
As preferably, described fermention medium is made up of 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L magnesium sulfate, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea, and pH value is 7.0-7.2.
Present invention also offers the application of aminoglycoside antibiotics in screening L-glutaminate superior strain.
As preferably, described aminoglycoside antibiotics is Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE.
From above technical scheme, deposit number of the present invention is the Corynebacterium glutamicum MHZ-0510 of CGMCC No.7939, and the ability that its fermentation generates L-glutaminate comparatively wild type glutamic acid bar bacterium significantly improves, L-glutaminate output increased 25.0%.Deposit number of the present invention be its fermentation of Corynebacterium glutamicum MHZ-0511 of CGMCC No.7940 generate L-glutaminate ability equally comparatively wild type glutamic acid bar bacterium significantly improve, L-glutaminate output increased 18.75%.Therefore, the Corynebacterium glutamicum of deposit number of the present invention to be CGMCC No.7939 and deposit number be CGMCC No.7940 can be widely used in the production of L-glutaminate.Corynebacterium glutamicum of the present invention obtains through the screening of the aminoglycoside antibiotics such as Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, it has the resistance to the aminoglycoside antibiotics such as Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, and improve L-glutaminate synthesis capability, thus L-glutaminate output is improved.Therefore, aminoglycoside antibiotics can be widely used in the screening of L-glutaminate.
The explanation of biological deposits information
Bacterial strain MHZ-0510: Classification And Nomenclature: Corynebacterium glutamicum, Corynebacterium glutamicum is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center on July 19th, 2013, address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica, deposit number is CGMCC No.7939.
Bacterial strain MHZ-0511: Classification And Nomenclature: Corynebacterium glutamicum, Corynebacterium glutamicum is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center on July 19th, 2013, address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica, deposit number is CGMCC No.7940.
Embodiment
The embodiment of the invention discloses Corynebacterium glutamicum and application thereof.Those skilled in the art can use for reference present disclosure, and suitable improving technique parameter realizes.Special needs to be pointed out is, all similar replacements and change apparent to those skilled in the art, they are all deemed to be included in the present invention.Bacterial strain of the present invention is described by preferred embodiment, related personnel obviously can not depart from content of the present invention, spirit and scope product as herein described is changed or suitably change with combination, realize and apply the technology of the present invention.
For realizing object of the present invention, the present invention adopts following technical scheme:
The present invention with wild type glutamic acid bar bacterium B498(purchased from Shanghai City Industry Wei Biological Research Institute) for starting strain, with N-methyl-N ＇ nitro-N nitrosoguanidine for mutagenic compound carry out chemomorphosis to it, then the suspension bacteria liquid of the Corynebacterium glutamicum B498 after mutagenesis is coated on respectively on the substratum containing Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE.From filtering out the bacterial strain with streptomycin resistance containing streptomycin medium, called after bacterial strain MHZ-0510.From filtering out the bacterial strain with neomycin resistance containing Liu Suanyan NEOMYCIN SULPHATE substratum, called after bacterial strain MHZ-0511.
The method of " common bacteria system identification handbook " that above-mentioned bacterial strain MHZ-0510 and MHZ-0511 filtered out edits according to the elegant pearl in east, Cai Miaoying is carried out physio-biochemical characteristics detection to it by the present invention, and detected result is consistent with wild type glutamic acid bar bacterium.In addition, analyze through 16S DNA detection, bacterial strain MHZ-0510 and MHZ-0511 and wild type glutamic acid bar bacterium homology, up to 99%, in conjunction with physiological and biochemical property, identify that it is Corynebacterium glutamicum.
For above-mentioned Corynebacterium glutamicum, present invention applicant is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center on July 19th, 2013, address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica, wherein, the deposit number of bacterial strain MHZ-0510 is CGMCC No.7939, and the deposit number of bacterial strain MHZ-0511 is CGMCC No.7940.
In an embodiment, the L-glutaminate of Corynebacterium glutamicum MHZ-0510, MHZ-0511 of the present invention and wild type glutamic acid bar bacterium B498 simultaneous test of fermenting shows, the L-glutaminate content of Corynebacterium glutamicum MHZ-0510 fermentation synthesis of the present invention is 4.0g/L, and the ferment L-glutaminate content of synthesis of wild type glutamic acid bar bacterium B498 is 3.2g/L, L-glutaminate output increased 25.0%.The ferment L-glutaminate content of synthesis of Corynebacterium glutamicum MHZ-0511 of the present invention is 3.8g/L, and the ferment L-glutaminate content of synthesis of wild type glutamic acid bar bacterium B498 is 3.2g/L, L-glutaminate output increased 18.75%.Showing that Corynebacterium glutamicum MHZ-0510 and MHZ-0511 of the present invention can be applied to produces in L-glutaminate, L-glutaminate output increased.Therefore, the invention provides Corynebacterium glutamicum MHZ-0510 and MHZ-0511 and producing the application in L-glutaminate, namely the Corynebacterium glutamicum of deposit number to be the Corynebacterium glutamicum of CGMCC No.7939 and deposit number be CGMCC No.7940 is producing the application in L-glutaminate.
In addition, present invention also offers a kind of L-glutaminate production method, the Corynebacterium glutamicum of to be CGMCCNo.7939 or deposit number by deposit number be CGMCC No.7940 is inoculated in seed culture medium, and to carry out expansion numerous, then by expand numerous after culture proceed to fermention medium fermentation, maintaining pH value between yeast phase is 4-8.
Wherein, as preferably, the pH value between yeast phase is 4.9-7.4.
Then production method of the present invention can be separated L-glutaminate according to this area ordinary method till can being performed until and no longer producing L-glutaminate.
Fermention medium for the numerous seed culture medium of expansion and fermentation is known in this field, and those skilled in the art all can adopt suitable substratum to carry out the fermentation of L-glutaminate.
As preferably, seed culture medium of the present invention is made up of 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L magnesium sulfate, 5.5g/L urea, and pH value is 7.0-7.2.
As preferably, fermention medium of the present invention is made up of 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L magnesium sulfate, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea, and pH value is 7.0-7.2.
Aminoglycoside antibiotics (Aminoglycosides) is the tobramycin antibiotic be formed by connecting by oxo bridge by aminosugar and aminocyclitol.There are the native amino glucosides classes such as the Streptomycin sulphate etc. from streptomycete, the gentamicin from micromonospora, also have the semi-synthetic aminoglycosides such as amikacin.Aminoglycoside antibiotics is for the synthesis of the effect mainly anti-bacteria protein of bacterium, point of application is at the aminoacyl site of the 16S RNA area decoder of cell 30S ribosomal subunit, it can affect the whole process of bacterioprotein synthesis, hinder the synthesis of initial recombination thing, Induction of bacterial resultant fault albumen and prevent the release of synthetic proteins, thus cause bacterial death.
Streptomycin sulphate and Liu Suanyan NEOMYCIN SULPHATE are aminoglycoside antibioticss, bacterioprotein is disturbed to synthesize by being incorporated on intracellular rrna, make it the protein of resulting anomaly, and bacterial cell membrane permeability is increased, important physiologically substance in cell is caused to leak outside and present germicidal action, comparatively strong to bacterium germicidal action stationary phase, be sterilization stationary phase class microbiotic.
At wild strain after the screening of the aminoglycoside antibiotics such as Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, may due to aminoglycoside antibioticss such as the protein resistant Streptomycin sulphate of described Corynebacterium glutamicum resulting anomaly or Liu Suanyan NEOMYCIN SULPHATEs, the protein of these exceptions causes L-glutaminate synthetase series to relieve the feedback inhibition of some product, thus cause the L-glutaminate output of mutant strain to be improved, or the glutamine translocator function on described Corynebacterium glutamicum cytolemma changes and facilitates the speed that glutamine goes out from intracellular transport, thus cause the L-glutaminate output of mutant strain to be improved.And Corynebacterium glutamicum MHZ-0510 and MHZ-0511 of the present invention obtains through Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE screening, be provided with the resistance to Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, and improve L-glutaminate synthesis capability.Therefore present invention also offers the application of aminoglycoside antibiotics in screening L-glutaminate superior strain.
As preferably, described aminoglycoside antibiotics is Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE.
In order to understand the present invention further, below in conjunction with embodiment, the present invention is described in detail.
Embodiment 1: the screening of Corynebacterium glutamicum MHZ-0510, MHZ-0511 of the present invention
Starting strain-wild type glutamic acid bar bacterium B498 is seeded in 30 DEG C of cultivations in LB liquid nutrient medium and obtains the bacteria suspension being in logarithmic phase in 10 hours, then this bacteria suspension is coated on LB solid plate, put by appropriate N-methyl-N ＇ nitro-N nitrosoguanidine solid particulate to LB solid plate central authorities, being placed in 30 DEG C of incubators cultivations had the lawn of faint growth to be suspended in appropriate stroke-physiological saline solution around scraping N-methyl-N ＇ nitro-N nitrosoguanidine particle after 16 hours.The physiological saline being suspended with lawn is coated on respectively on the LB solid plate containing 1.0mg/L Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, 30 DEG C are continued cultivation 2 days, according to the feature such as colonial morphology, color picking list bacterium colony, wherein from filtering out the bacterial strain with streptomycin resistance containing streptomycin medium, called after bacterial strain MHZ-0510.From filtering out the bacterial strain with neomycin resistance containing Liu Suanyan NEOMYCIN SULPHATE substratum, called after bacterial strain MHZ-0511.
LB liquid nutrient medium/LB solid plate formula is as follows: extractum carnis 5g, peptone 10g, NaCl5g, vitamin H 50 μ g, VitB1 100 μ g, leucine 100mg, homoserine 100mg, Threonine 100mg, methionine(Met) 100mg, agar 18g, dissolves and be settled to 1000mL after regulating pH to 6.8-7.4 with distilled water.
Wherein, the difference of LB liquid nutrient medium and LB solid plate is whether agar adds.Vitamin H, VitB1, leucine, homoserine, Threonine, the nonessential interpolation of methionine(Met), can add according to actual needs.
The method of " the common bacteria system identification handbook " edited according to the elegant pearl in east, Cai Miaoying by above-mentioned bacterial strain MHZ-0510, MHZ-0511 filtered out carries out physio-biochemical characteristics detection to it, and detected result is consistent with wild type glutamic acid bar bacterium.In addition, analyze through 16S DNA detection, bacterial strain MHZ-0510 and MHZ-0511 and wild type glutamic acid bar bacterium homology, up to 99%, in conjunction with physiological and biochemical property, identify that it is Corynebacterium glutamicum.
Embodiment 2: L-glutaminate production method of the present invention and L-glutaminate fermentation simultaneous test
1, fermentation process
Corynebacterium glutamicum MHZ-0510 and MHZ-0511 of the present invention is seeded in respectively expand in the seed culture medium of the following stated numerous, in 30 DEG C of shaking culture 16 hours, gained culture is inoculated in the fermention medium of the following stated, the volume ratio of culture and fermention medium is that 1:10(those skilled in the art suitably can regulate according to the amount of the fermention medium in actual production, this ratio is preferred proportion), 30 DEG C of shaking culture are to no longer producing L-glutaminate (being generally 72 hours).In the fermentation medium during shaking culture, the pH value in maintenance fermention medium is between 6.5-7.4.
Seed culture medium: 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L magnesium sulfate, 5.5g/L urea form, and pH value is 7.0-7.2.
Fermention medium: 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L magnesium sulfate, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea form, and pH value is 7.0-7.2.
2, L-glutaminate fermentation simultaneous test
Corynebacterium glutamicum MHZ-0510, MHZ-0511 of the present invention and wild type glutamic acid bar bacterium B498 are fermented according to aforementioned production method simultaneously, yeasting, the inoculum size of three kinds of bacterial strains are all identical, measure the L-glutaminate content synthesized by three kinds of bacterial strains after stopping fermentation by bio-sensing instrument.
Result shows, and wild type glutamic acid bar bacterium B498 output is 3.2g/L, and Corynebacterium glutamicum MHZ-0510 output of the present invention is 4.0g/L, and its L-glutaminate output comparatively starting strain wild type glutamic acid bar bacterium B498 improves 25.0%.Corynebacterium glutamicum MHZ-0511 output of the present invention is 3.8g/L, and its L-glutaminate output comparatively starting strain wild type glutamic acid bar bacterium B498 improves 18.75%.Show deposit number of the present invention to be the Corynebacterium glutamicum MHZ-0510 of CGMCC No.7939 and deposit number be that the Corynebacterium glutamicum MHZ-0511 of the CGMCC No.7940 ability generating L-glutaminate of fermenting significantly improves, the fermentative production of L-glutaminate can be widely used in.
The explanation of above embodiment just understands method of the present invention and core concept thereof for helping.It should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention, can also carry out some improvement and modification to the present invention, these improve and modify and also fall in the protection domain of the claims in the present invention.
Claims (8)
1. a Corynebacterium glutamicum, is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, and deposit number is CGMCC No.7939.
2. deposit number is the application of Corynebacterium glutamicum in production L-glutaminate of CGMCC No.7939.
3. a Corynebacterium glutamicum, is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, and deposit number is CGMCC No.7940.
4. deposit number is the application of Corynebacterium glutamicum in production L-glutaminate of CGMCC No.7940.
5. the production method of a L-glutaminate, it is characterized in that, the Corynebacterium glutamicum of to be CGMCC No.7939 or deposit number by deposit number be CGMCC No.7940 is inoculated in seed culture medium, and to carry out expansion numerous, then by expand numerous after culture proceed to fermention medium fermentation, maintaining pH value between yeast phase is 4-8.
6. production method according to claim 5, it is characterized in that, the pH value between described yeast phase is 4.9-7.4.
7. production method according to claim 5, it is characterized in that, described seed culture medium is made up of 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L magnesium sulfate, 5.5g/L urea, and pH value is 7.0-7.2.
8. production method according to claim 5, it is characterized in that, described fermention medium is made up of 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L magnesium sulfate, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea, and pH value is 7.0-7.2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310351990.9A CN103374540B (en) | 2013-08-13 | 2013-08-13 | Corynebacterium glutamicum and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310351990.9A CN103374540B (en) | 2013-08-13 | 2013-08-13 | Corynebacterium glutamicum and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103374540A CN103374540A (en) | 2013-10-30 |
| CN103374540B true CN103374540B (en) | 2015-04-22 |
Family
ID=49460373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310351990.9A Active CN103374540B (en) | 2013-08-13 | 2013-08-13 | Corynebacterium glutamicum and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103374540B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106148440A (en) * | 2016-08-10 | 2016-11-23 | 洛阳华荣生物技术有限公司 | Fermentative Production gamatine |
| CN107227283A (en) * | 2017-05-26 | 2017-10-03 | 廊坊梅花生物技术开发有限公司 | A kind of Corynebacterium glutamicum and its construction method and application |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105861361A (en) * | 2016-04-13 | 2016-08-17 | 福建省微生物研究所 | Application of Corynebacterium glutamicum FX69 in purification of piggery wastewater anaerobic effluent |
| CN106119181B (en) * | 2016-06-30 | 2019-09-03 | 江南大学 | A kind of genetic engineering bacterium and its application method producing polyhydroxybutyrate hydroxyl valerate |
| CN105950517B (en) * | 2016-06-30 | 2019-05-17 | 江南大学 | A kind of Corynebacterium glutamicum and its application |
| CN106065411B (en) * | 2016-08-10 | 2021-12-07 | 洛阳华荣生物技术有限公司 | Production of creatine by fermentation method |
| CN112812985B (en) * | 2020-11-11 | 2023-01-10 | 新疆阜丰生物科技有限公司 | Method for improving acid production of glutamine fermentation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1451047A (en) * | 1999-06-25 | 2003-10-22 | Basf公司 | Corynebacterium glutamicum genes encoding stress resistance and tolerance proteins |
| DE19953206A1 (en) * | 1999-11-05 | 2001-05-10 | Degussa | Plasmids from Corynebacterium glutamicum and their use |
| BR0211745A (en) * | 2001-08-06 | 2004-10-13 | Degussa | Corineform bacteria producing chemical compounds ii |
| EP1414970A2 (en) * | 2001-08-06 | 2004-05-06 | Degussa AG | Production of l-lysine by genetically modified corynebacterium glutamicum strains |
-
2013
- 2013-08-13 CN CN201310351990.9A patent/CN103374540B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106148440A (en) * | 2016-08-10 | 2016-11-23 | 洛阳华荣生物技术有限公司 | Fermentative Production gamatine |
| CN107227283A (en) * | 2017-05-26 | 2017-10-03 | 廊坊梅花生物技术开发有限公司 | A kind of Corynebacterium glutamicum and its construction method and application |
| CN107227283B (en) * | 2017-05-26 | 2021-01-15 | 廊坊梅花生物技术开发有限公司 | Corynebacterium glutamicum and construction method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103374540A (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103374540B (en) | Corynebacterium glutamicum and application thereof | |
| CN102517239B (en) | A microorganism having enhanced L-valine productivity and process for preparing L-valine using the same | |
| CN104745513A (en) | Pyrroloquinoline-quinone-producing Hyphomicrobium strain and application thereof | |
| CN102653725B (en) | Bacillus coagulans and application thereof in mixed fermentation to produce L-lactic acid | |
| CN102925504B (en) | Method and fermentation culture medium used for synthesizing gamma-aminobutyric acid through microbial fermentation | |
| CN101285046A (en) | Mutant strain streptomyces albus TUST2 and process for producing epsilon-polylysine and salts thereof by using the mutant strain | |
| CN110373359A (en) | A kind of streptomyces albus X-18 and the method using bacterium production epsilon-polylysine | |
| JPH03232497A (en) | Production of l-glutamine by fermentation | |
| US10053744B2 (en) | Yeast strain with high yield of glutathione | |
| WO2012016445A1 (en) | Bacillus subtilis strain and uses thereof | |
| CN102653724A (en) | Lactobacillus casei and application thereof to produce L-lactic acid by fermentation | |
| JPS5816872B2 (en) | Corynebacterium glutamicum mutant strain | |
| CN104726381B (en) | One plant of bacterial strain for producing L lysines and its method for producing L lysines | |
| CN1181191C (en) | Microorganism producing 5'-inosinic acid and process for producing 5'-inosinic acid using the same | |
| JP6857041B2 (en) | Carnosine production method and new microorganisms | |
| CN110129225A (en) | γ~polyglutamic acid producing strains and breeding prepare γ~polyglutamic acid method | |
| CN110656065B (en) | Streptomyces for producing epsilon-polylysine and application thereof | |
| CN105861373B (en) | It is a kind of produce keratinase pseudomonas aeruginosa and its application | |
| CN115895974A (en) | Lactobacillus plantarum rich in selenium and capable of producing gamma-aminobutyric acid at high yield and application of lactobacillus plantarum | |
| CN102382787B (en) | Corynebacterium pekinense and application thereof | |
| CN103184180A (en) | Lactobacillus buchneri for producing mannitol, and method for producing mannitol by fermentation | |
| JPS5886094A (en) | Preparation of l-lysine by fermentation | |
| CN103305437A (en) | L-ammonium lactate tolerant bacterium and application thereof | |
| CN105483060B (en) | A kind of Corynebacterium glutamicum of high yield citrulling and its application in fermenting and producing citrulling | |
| CN102399732B (en) | Beijing corynebacterium and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |